Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.67 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.67 |
| ▸ | STAT3 | P40763 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | MIF | P14174 | 3/20 | 0.58 |
| ▸ | BCL2 | P10415 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869200 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22325167 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242290 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL21333201 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20142514 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189563 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL20242552 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL22834201 | 1.00 | CRBN (0.68) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL21179283 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 | |
| SCHEMBL30189483 | 0.99 | CRBN (0.69) | CRBNDDB1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734989-A2 | SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1) | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006902-A2 | SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-11-14 | — | — | US | disclosed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| WO-2024078581-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND USES THEREOF | APPICINE THERAPEUTICS (HK) LIMITED (CN) | 2024-04-18 | — | — | WO | disclosed |
| EP-4288434-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoires Servier (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| EP-4146660-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| CN-115605488-A | Bifunctional degradants of hematopoietic progenitor kinases and therapeutic uses thereof | 新锐思生物制药股份有限公司（US） | 2023-01-13 | — | — | CN | disclosed |
| WO-2020162725-A1 | TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885DDB1 987/4885HDAC3 231/4885 |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885DDB1 148/4885HDAC3 623/4885 |
| US-20240376094-A2 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | CRBN 1/4885DDB1 148/4885HDAC3 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.